Innovative Humanized Nanobody Targeting ALB and CX3CR1 for Advanced Glomerulonephritis Therapy

VHH-P433 is a next-generation, humanized nanobody designed to simultaneously target albumin (ALB) and C-X3-C motif chemokine receptor 1 (CX3CR1). Engineered for optimal efficacy, VHH-P433 is currently in the Biological Testing stage and shows significant promise for the treatment of glomerulonephritis. By leveraging dual molecular specificity, VHH-P433 introduces a novel therapeutic approach focused on modulating key pathways involved in glomerular injury and inflammation. Its unique design positions it as a leading candidate in the quest for more effective interventions for glomerulonephritis, a disease with substantial unmet clinical needs.

Licensing Opportunity

VHH-P433 is now available for out-licensing and collaborative partnerships. We welcome inquiries from biopharmaceutical companies interested in advancing this promising nanobody program for glomerulonephritis therapy and beyond.

Development Phase

Modality

VHH-P433 utilizes a multivalent immunoglobulin single variable domain (VHH) architecture, featuring a C-terminal alanine and consisting of three antibody-derived binding domains. Two of these domains are sequence-optimized, humanized anti-CX3CR1 single-domain antibodies and the third is an anti-human serum albumin VHH, all joined by a flexible 9GS peptide linker. The configuration, with specific sequence and mutation innovations, enhances the molecule’s tissue penetration and stability, both characteristic advantages of VHH (nanobody) modality. This small-size, monomeric structure allows VHH-P433 to efficiently traverse renal barriers and inflammatory sites, which is crucial in treating glomerulonephritis involving complex glomerular filtration structures.

Target

ALB and CX3CR1 are both crucial molecular targets in the context of glomerulonephritis. ALB serves as a major plasma protein involved in osmotic regulation and transport, predominantly expressed in the liver and widely distributed in plasma. CX3CR1 is a chemokine receptor broadly expressed on immune cells such as monocytes, macrophages, and subsets of T cells, where it mediates leukocyte trafficking and inflammation. In glomerulonephritis, dysregulated ALB dynamics reflect renal damage, while CX3CR1-driven immune cell infiltration exacerbates glomerular injury. The dual targeting of ALB and CX3CR1 by VHH-P433 offers strategic value: addressing renal function maintenance via ALB and modulating inflammation via CX3CR1. This multi-pronged approach leverages both ALB and CX3CR1 as disease-relevant nodes, amplifying therapeutic impact in glomerulonephritis.

Mechanism of Action

VHH-P433 acts by specifically binding to ALB and CX3CR1. Its anti-ALB domain enhances serum half-life, improves pharmacokinetic profiles, and facilitates renal targeting, while the anti-CX3CR1 domains interrupt immune cell recruitment and inflammatory responses within the glomeruli. By modulating both the retention and distribution of the therapeutic agent via ALB binding and reducing CX3CR1-mediated leukocyte infiltration, VHH-P433 aims to mitigate glomerular inflammation and injury. The modular design of the nanobody format also allows potential expansion into antibody-drug conjugates or multispecific constructs, further broadening its therapeutic utility in other immune-mediated or renal conditions.

Glomerulonephritis

Glomerulonephritis encompasses a diverse group of diseases characterized by inflammation of the glomeruli within the kidney, leading to proteinuria, hematuria, and progressive renal dysfunction. It represents a significant global health concern, affecting both adult and pediatric populations. The underlying mechanisms often involve immune-mediated injury, with contributions from both humoral and cellular responses. Current treatment strategies primarily include immunosuppressive agents, plasma exchange, and in severe cases, dialysis or kidney transplantation. However, these approaches are often associated with drug-related toxicity, suboptimal efficacy, and high relapse rates. There remains a critical unmet need for targeted therapies that can address pathogenic inflammation while preserving renal function, especially in refractory or relapsing cases. VHH-P433 introduces a novel modality, offering dual targeting of ALB and CX3CR1, aiming to reduce inflammation and protect glomerular integrity. Its innovative mechanism and structural benefits hold promise for enhanced efficacy and safety in the management of glomerulonephritis.